#United States #Palo Alto #ESMO #Riboscience #RBS2418

Riboscience's Breakthrough Presentation at ESMO 2026

Riboscience, a pioneering clinical-stage biotechnology company focused on developing first-in-class immunotherapies, is gearing up for a significant announcement at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. This event will take place from October 23 to 27 in Madrid, Spain. Notably, the company will present pivotal findings from its Phase 1b study concerning RBS2418, an innovative oral ENPP1 inhibitor.

The Highlights of RBS2418's Phase 1b Study

The poster presentation slated for October 24 will showcase critical data about overall survival and immune response in patients with advanced, metastatic solid tumors. With a focus on colorectal cancer (CRC), the study's safety, pharmacokinetic, and pharmacodynamic outcomes will be revealed, reflecting results from a total of 89 participants. This investigation marks a significant step not only for Riboscience but also for the broader field of cancer treatment, as it presents the first ENPP1 inhibitor ever evaluated in clinical settings.

Klaus Klumpp, Co-founder and President of Riboscience, expressed excitement about the preliminary outcomes, stating, "As the first ENPP1 inhibitor in the clinic, RBS2418 is bringing a new type of immunotherapy to the field. Seeing immune activation in cold tumors from a simple oral monotherapy is very exciting, and we are proud to share our first long-term survival outcomes at ESMO."

Mechanism of Action

RBS2418 operates by targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), which has high affinity and selectivity. The expression of ENPP1 and cyclic GMP-AMP synthase (cGAS) in solid tumors is crucial, as ENPP1 is linked to immune evasion and the creation of what is known as a “cold tumor” microenvironment. RBS2418 aims to counteract this by blocking ENPP1, thereby bolstering the body's innate anti-tumor immune response.

The clinical significance is profound: RBS2418 doesn’t just work as a standalone treatment in advanced cancers, but it is also being investigated in combination with existing cancer therapies. This dual approach may enhance its effectiveness and potentially lead to improved outcomes for patients suffering from aggressive malignancies.

Collaboration with ESMO

The presentation at ESMO is part of a broader effort to engage with the global oncology community and synthesize insights that can drive further research and clinical trials in immunotherapy. By fostering collaboration, the team at Riboscience hopes that findings from studies like these will instigate new dialogue among researchers and practitioners alike regarding the future of cancer treatments, especially those that leverage the immune system.

About Riboscience

Based in the San Francisco Bay Area, Riboscience distinguishes itself through its proprietary platform that utilizes a unique library of nucleoside and non-nucleoside analogs to forge innovative drug candidates for treating a variety of diseases, including cancers and infectious diseases. The company's relentless commitment to scientific advancement encapsulates their ambition to redefine therapeutic possibilities through cutting-edge research.

For more information about their ongoing research, you can visit Riboscience’s official website.

As the ESMO Congress 2026 approaches, all eyes will be on Riboscience and the exciting data they are set to reveal, marking a significant milestone in the fight against cancer.